A carregar...
Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial
BACKGROUND: Guidelines recommend reducing elevated serum phosphate in patients with CKD. Tenapanor, a minimally absorbed inhibitor of gastrointestinal sodium/hydrogen exchanger 3 (NHE3), reduces paracellular phosphate transport. METHODS: In this phase 3 randomized, double-blind trial, we randomly as...
Na minha lista:
| Publicado no: | J Am Soc Nephrol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Nephrology
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6442342/ https://ncbi.nlm.nih.gov/pubmed/30846557 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2018080832 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|